Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer

PD1 blockade to reinvigorate T cells has become part of standard of care for patients with NSCLC across disease stages. However, the majority of patients still do not respond. One potential mechanism of resistance is increased expression of other checkpoint inhibitory molecules on T cells leading to...

Full description

Bibliographic Details
Main Authors: Marina Martinez, Soyeon Kim, Naomi St. Jean, Shaun O’Brien, Lurong Lian, Jing Sun, Raluca I. Verona, Edmund Moon
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:OncoImmunology
Subjects:
checkpoint blockade
tim3
tigit
lung cancer
adoptive t cell therapy
Online Access:http://dx.doi.org/10.1080/2162402X.2021.1873607

Internet

http://dx.doi.org/10.1080/2162402X.2021.1873607

Similar Items